Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Clinical Trial ID NCT00658086

Rank	Title	Journal	Year	PubWeight™‹?›
1	Delivery materials for siRNA therapeutics.	Nat Mater	2013	3.70
2	RNA therapeutics: beyond RNA interference and antisense oligonucleotides.	Nat Rev Drug Discov	2012	3.70
3	RNA-based therapeutics: current progress and future prospects.	Chem Biol	2012	3.01
4	Current progress of siRNA/shRNA therapeutics in clinical trials.	Biotechnol J	2011	2.17
5	RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.	Am J Respir Crit Care Med	2010	1.94
6	RNAi therapies: drugging the undruggable.	Sci Transl Med	2014	1.26
7	Preclinical and clinical development of siRNA-based therapeutics.	Adv Drug Deliv Rev	2015	1.01
8	Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.	Nanomedicine (Lond)	2014	0.94
9	Clinical Translation of Nanomedicine.	Chem Rev	2015	0.93
10	Technologies for controlled, local delivery of siRNA.	J Control Release	2015	0.80
11	siRNA-based topical microbicides targeting sexually transmitted infections.	Curr Opin Mol Ther	2010	0.79